BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 20618328)

  • 1. High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients.
    Kastritis E; Roussou M; Michael M; Gavriatopoulou M; Michalis E; Migkou M; Delimpasi S; Kyrtsonis MC; Gogos D; Liapis K; Charitaki E; Repousis P; Terpos E; Dimopoulos MA;
    Br J Haematol; 2010 Sep; 150(5):587-91. PubMed ID: 20618328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity.
    Anagnostopoulos A; Eleftherakis-Papaiakovou V; Kastritis E; Tsionos K; Bamias A; Meletis J; Dimopoulos MA; Terpos E
    Br J Haematol; 2007 Jun; 137(6):560-8. PubMed ID: 17451406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H; Wierzbowska A; Robak T
    Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma.
    Tsirakis G; Pappa CA; Kanellou P; Stratinaki MA; Xekalou A; Psarakis FE; Sakellaris G; Alegakis A; Stathopoulos EN; Alexandrakis MG
    Hematol Oncol; 2012 Sep; 30(3):131-6. PubMed ID: 21919032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.
    Anargyrou K; Terpos E; Vassilakopoulos TP; Pouli A; Sachanas S; Tzenou T; Masouridis S; Christoulas D; Angelopoulou MK; Dimitriadou EM; Kalpadakis C; Tsionos K; Panayiotidis P; Dimopoulos MA; Pangalis GA; Kyrtsonis MC;
    Haematologica; 2008 Mar; 93(3):451-4. PubMed ID: 18287135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients.
    Pappa CA; Alexandrakis MG; Boula A; Psarakis FE; Kolovou A; Bantouna V; Stavroulaki E; Tsirakis G
    Hematol Oncol; 2013 Dec; 31(4):201-5. PubMed ID: 23576184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
    Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
    Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas.
    Pavel ME; Hassler G; Baum U; Hahn EG; Lohmann T; Schuppan D
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):434-43. PubMed ID: 15807874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating angiogenic factors during periovulation and the luteal phase of normal menstrual cycles.
    Malamitsi-Puchner A; Sarandakou A; Tziotis J; Stavreus-Evers A; Tzonou A; Landgren BM
    Fertil Steril; 2004 May; 81(5):1322-7. PubMed ID: 15136097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression.
    Molica S; Vitelli G; Levato D; Giannarelli D; Vacca A; Cuneo A; Ribatti D; Digiesi G
    Eur J Haematol; 2004 Jul; 73(1):36-42. PubMed ID: 15182336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenic protein expression in advanced epithelial ovarian cancer.
    Barton DP; Cai A; Wendt K; Young M; Gamero A; De Cesare S
    Clin Cancer Res; 1997 Sep; 3(9):1579-86. PubMed ID: 9815846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
    Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic regulation of angiogenesis and matrix degradation in bone regeneration--distraction osteogenesis compared to rigid fracture healing.
    Weiss S; Zimmermann G; Baumgart R; Kasten P; Bidlingmaier M; Henle P
    Bone; 2005 Dec; 37(6):781-90. PubMed ID: 16202678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal cell carcinoma: relevance of angiogenetic factors.
    Wechsel HW; Bichler KH; Feil G; Loeser W; Lahme S; Petri E
    Anticancer Res; 1999; 19(2C):1537-40. PubMed ID: 10365140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating biomarkers of angiogenesis as indicators of left ventricular systolic dysfunction amongst patients with coronary artery disease.
    Patel JV; Abraheem A; Chackathayil J; Gunning M; Creamer J; Hughes EA; Lip GY
    J Intern Med; 2009 May; 265(5):562-7. PubMed ID: 19187100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of angioregulatory mediators in healthy individuals depend on age and physical activity: studies of angiogenin, basic fibroblast growth factor, leptin and endostatin.
    Bruserud O; Grovan F; Lindås R; Blymke Møinichen C; Osterhus KK
    Scand J Clin Lab Invest; 2005; 65(6):505-11. PubMed ID: 16179284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenic factors are elevated in overweight and obese individuals.
    Silha JV; Krsek M; Sucharda P; Murphy LJ
    Int J Obes (Lond); 2005 Nov; 29(11):1308-14. PubMed ID: 15953938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.